News Release
More-
July 30, 2025
Licensing Agreement with Viridian Therapeutics for "Veligrotug" and "VRDN-003" in Treatment of Thyroid Eye Disease -
July 29, 2025
Notice Concerning Revisions to Financial Results Forecast and Recording of Extraordinary Income -
July 24, 2025
Notice Regarding Completion of Disposal of Treasury Stocks as Restricted Stock for Members of the Board and Corporate Officers -
July 1, 2025
New Launch of TAVALISSE® for Chronic Idiopathic Thrombocytopenic Purpura Treatment in South Korea -
June 24, 2025
Notice Concerning Disposal of Treasury Shares as Restricted Stock for Members of the Board and Corporate Officers
Topics
More-
July 29, 2025
The First Quarter of FY2025 (July 29, 2025) -
July 29, 2025
R&D Pipeline as of July 2025 -
June 27, 2025
Status of Dialogue with Shareholders and Investors (June 27, 2025) -
May 7, 2025
Financial Results (May 7, 2025) -
February 3, 2025
The Third Quarter of FY2024 (February 3, 2025)
